Immune Pathways

This work suggests a new experimental target (extracellular vimentin) that reduced inflammation, fibrosis-related markers, and necroptotic cell-death markers in mice and in cultured colon cells — processes that are...

Researchers identified a plant-derived compound that reduced inflammation, oxidative stress, and gut dysbiosis in a mouse model of ulcerative colitis; this could point to new mechanistic leads for future therapies...

New Phase 2a data suggest a combination therapy (ABBV-466) produced higher endoscopic remission at Week 24 than either component alone — a potential sign that multi-target approaches might improve Crohn's outcomes.

Mid-stage data suggest a dual-targeting approach may improve endoscopic remission for people with moderate–severe Crohn's disease, including many who previously failed advanced therapies. If confirmed in larger trials,...

The findings suggest that tissue-based immune profiling may better identify biologically distinct subgroups in ulcerative colitis than blood tests, which could affect research on personalized treatment or trial...

People with Crohn’s disease or ulcerative colitis may have higher cardiovascular risk; this prospective study aims to measure how often major heart and vascular events occur in IBD and to find biological and clinical...

The paper suggests a specific gut bacterium and its metabolite can protect against intestinal inflammation in mice by acting on enteric neurons, revealing a new neuro-immune pathway that could inform future IBD...

This research links a gut bacterial metabolite to modulation of an immune receptor (GPR183) that is elevated in colon/rectum of ulcerative colitis patients, suggesting a possible microbiota‑to‑immune pathway relevant to...

The review links ER stress and mitochondrial dysfunction to core IBD processes (inflammation, barrier damage, cell death) and highlights MERCs as an integrated signaling hub, suggesting new biomarker and therapeutic...

People with ulcerative colitis often face trial‑and‑error when starting advanced therapies. THAMES‑IBD aims to find biological and psychosocial markers that predict who will respond, which could eventually make treatment...

If validated, mucosal biomarkers like SPARC and SPP1 might help predict who will not respond to infliximab, potentially guiding treatment choices and avoiding ineffective therapy for some people with UC.

Preclinical work identifies a natural-product mixture that reduced inflammation, improved gut barrier markers, and changed the microbiome in a mouse model of ulcerative colitis. This could be an early step toward new...

Oxidative stress may be a key driver of inflammation in IBD and could point to new biomarkers or adjunctive treatments (dietary changes, antioxidant strategies, or targeted pathways like Nrf2 and ferroptosis) that...

Patients with refractory IBD or those not fully responding to single targeted therapies may be interested because ACT aims to control multiple inflammatory pathways and could offer improved symptom and endoscopic...

This review reframes IBD as a systemic disease influenced by gut microbes, metabolism, and immune interactions — which matters because it points toward better ways to stratify patients, monitor disease, and personalize...

The study suggests ulcerative colitis shows greater mucosal immune variability across sex, age and severity than Crohn’s disease, which could affect how patients are grouped for research or future personalized...

The review highlights marine polysaccharides as multi-target agents that could modulate inflammation, the microbiome, and the gut barrier—processes central to ulcerative colitis—and points to possible roles as functional...

Identifying a genetic cause (XIAP frameshift variant) helped explain why anti‑TNF drugs failed and why blocking IL‑12/23 with ustekinumab led to improvement; that connection could influence treatment choices for similar...

People with IBD may be concerned about environmental exposures that could influence inflammation or worsen disease. This review explains why micro- and nanoplastics are biologically plausible contributors but also why...

The article highlights a natural gut-microbe product (urolithin A) that may help repair the intestinal lining by activating a protective molecular pathway.

Researchers are testing whether blocking three inflammation pathways at once can reduce tissue inflammation more than single drugs. If ex vivo results show stronger effects, it could guide development of multi-target...

This study identifies reproducible molecular patterns in UC tissue that could help researchers target non-immune pathways (metabolic/mitochondrial) in addition to inflammation, and it highlights that apparently...

This project tests whether common nanoplastics that people ingest could damage the gut barrier, alter gut microbes’ estrogen metabolism, and injure enteric nerves — processes that might increase risk or severity of IBD.

Researchers are exploring whether vagus nerve stimulation or drugs targeting the α7 nicotinic receptor could reduce liver inflammation from heavy alcohol use. If mechanisms are confirmed, this could point to new...

If confirmed, molecular or microbial markers found at surgery could help identify Crohn’s patients at higher risk of postoperative endoscopic recurrence and inform closer monitoring or preventative strategies after...

This preclinical study suggests that a specific gut microbe (Bacteroides acidifaciens) and the bile acid UDCA can reduce inflammation in a mouse colitis model by improving barrier function and dampening NLRP3-driven...

JAK inhibitors are used to treat IBD and act broadly on immune signalling; understanding their cell-specific effects may explain who benefits, who doesn’t, and why adverse effects occur. This is directly relevant to...

If you or someone you care for is not responding to anti‑TNF drugs for ulcerative colitis, this review explains biological reasons why that may happen and points toward research directions that could lead to better tests...

The study maps cell-level programs in ileum and colon that associate with failure to respond to biologic therapies, suggesting specific cellular markers and niches that could help explain treatment resistance and guide...

Researchers are exploring natural compounds that might reduce intestinal inflammation and rebalance the gut microbiome. If translatable to humans, such approaches could inform new treatments or adjunctive therapies for...

The study points to CD226 (DNAM-1) being linked to inflammatory and interferon-driven programs in specific intestinal immune cells in Crohn's disease, which may be relevant to understanding disease mechanisms or...

The paper suggests gut bacteria make an anti-inflammatory metabolite (NOP) that accumulates in IBD and reduces inflammatory responses in cells and multiple mouse colitis models, pointing to a potential microbiome-derived...

These development programs could expand treatment choices for Crohn’s disease and may eventually address fibrosis and refractory disease—two major unmet needs. Progress in trials could change management options in coming...

The study links TXNIP/NLRP3 inflammatory signaling to disease features in an animal UC model and tests engeletin and rosuvastatin as interventions that lowered inflammatory markers—information relevant to researchers...

The study links NAD+ precursor (NMN) supplementation to changes in TGF-β–associated gene programs, intestinal immune signatures, and the gut microbiome in mouse colitis models — pathways relevant to fibrosis and...

If validated, IGFBP5 or its downstream pathway could help predict who will not respond to anti-TNF therapy and point to new targets to overcome resistance.

This review may help patients and clinicians understand how long-lasting changes in bacterial metabolism could contribute to IBD relapse and point toward future microbiome-targeted therapies aimed at restoring resilient...

The study introduces a novel preclinical therapeutic approach that selectively degrades HDAC6 and reduced inflammation in a mouse model of colitis, suggesting a potential new drug-discovery avenue relevant to ulcerative...

If you have IBD, the mouth and gums may be part of shared inflammatory pathways with your gut. Periodontitis is associated with higher odds of having IBD in cross-sectional studies and has a modest link to later...

This review suggests Aloe vera polysaccharides could support gut barrier repair, microbiome balance, and immune regulation—mechanisms relevant to IBD inflammation and healing. However, evidence is mainly preclinical and...

The study explores a novel, combined nanozyme + microbiome-derived vesicle approach aimed at reducing oxidative stress and modulating inflammation in IBD — mechanisms that are relevant to disease pathways and future...

Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.

Researchers are exploring natural compounds that may modulate gut microbes, barrier function, and immune signaling relevant to ulcerative colitis.

This study describes a new plant-derived nanoparticle (EBDEVs) that reduced inflammation and improved colon health in a mouse model of ulcerative colitis and altered the gut microbiota — early evidence that may guide...

This study reports a new colon-targeted delivery system for unconjugated bilirubin that reduced inflammation and improved mucosal healing in a mouse model of ulcerative colitis; it could inform future drug-development...

Finding shared genes (CLDN8, ABCA12) suggests common inflammatory mechanisms between ulcerative colitis and psoriasis, which could inform future biomarkers or therapies relevant to patients with either or both...

This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...

Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...